Using exercise to manage high blood sugar after missed insulin doses
Official title: Physical Activity to Prevent and Treat Hyperglycemia From a Mistimed Bolus Insulin Dose: The MISSED DOSE Study
Run by Institut de Recherches Cliniques de Montreal · NCT06686329 · Data updated 2026-11-12
This study is testing if brisk walking after missing insulin can help young adults with type 1 diabetes keep their blood sugar levels in check.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years to 24 Years |
| Sex | All |
| Enrollment | 30 (estimated) |
| Sponsor | Institut de Recherches Cliniques de Montreal Academic / other |
| Locations | 1 site (Montreal, Quebec) |
| Status | Recruiting |
| Started | March 17, 2025 |
| Main results expected | April 30, 2026 |
| Study ends | September 30, 2026 |
| Registry record updated | March 12, 2026 |
| Trial ID | NCT06686329 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are young adults aged 18-24 years with type 1 diabetes who have been diagnosed for at least two years and use a Dexcom G7 continuous glucose monitor.
✕Probably not a fit
Patients who may not benefit from this study include those with conditions that could make exercise harmful, such as significant renal disease or gastroparesis.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This study investigates the impact of combining brisk walking with a post-prandial insulin dose on blood glucose levels in individuals with type 1 diabetes who miss their pre-meal insulin. Participants will be monitored using continuous glucose monitors (CGMs) to assess the effectiveness of this approach in preventing hyperglycemia. The study focuses on young adults aged 18-24 years who have been diagnosed with type 1 diabetes for at least two years and have a recent glucose management indicator below 9.9%. By understanding the relationship between exercise and insulin timing, the study aims to provide practical solutions for managing blood sugar levels more effectively.
Why it matters
Potential benefit: If successful, this approach could help patients better manage their blood sugar levels after missed insulin doses, potentially reducing the risk of complications associated with hyperglycemia.
How similar studies have gone: While the specific combination of exercise and mistimed insulin dosing is novel, previous studies have shown that physical activity can positively influence blood glucose management in diabetes.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adults aged 18-24 years * Type 1 diabetes diagnostic for at least two years * Estimated glycated hemoglobin or glucose management indicator obtained from the past 30 days of CGM data of \< 9.9% * Use a Dexcom G7 CGM in routine care Exclusion Criteria: * Changes in insulin management strategy within the past 2 months * Diagnosis of gastroparesis * Having a condition that could render exercise harmful * Intolerance to gluten and lactose * Having significant renal disease (e.g., eGRF \< 30 ml/min) * Inability to provide informed consent due to cognitive deficit * Currently taking other medications (other than insulin) that may alter glucose metabolism (e.g., non-insulin antihyperglycemic drugs such as sglt2-inhibitors, corticosteroids), unless dosages thereof have been stable for more than three months * For women, being pregnant or breastfeeding
Where it's running
-
Institut de recherches cliniques de Montréal
Montreal, Quebec, Canada Recruiting
Study contacts
- Study coordinator: Corinne Suppère, MSc
- Email: corinne.suppere@ircm.qc.ca
- Phone: 514-987-5597
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
VV-14300: a gene therapy approach for adults with type 1 diabetes not well controlled on an automated insulin system
This trial tests VV-14300 in adults with type 1 diabetes who aren’t reaching their blood sugar goals despite using an automated insulin delivery system.
-
New gene therapies VV-14299 and VV-14300 for adults with Type 1 Diabetes failing automated insulin delivery
This study tests VV-14299 and VV-14300, or VV-14300 alone, in adults with long-standing Type 1 Diabetes whose blood sugar remains poorly controlled despite using an automated insulin delivery system.
-
Oral verapamil in newly diagnosed children and teens with type 1 diabetes
This study tests whether taking verapamil by mouth can help preserve pancreatic beta cells and reduce insulin needs in kids and teens with recently diagnosed type 1 diabetes.
-
Preventing device-related skin rashes in kids with type 1 diabetes using hydrocolloid vs silicone patches
This study tests whether silicone-based or hydrocolloid patches help prevent recurring skin irritation from insulin pumps or CGMs in children and teens with type 1 diabetes.
-
AI-assisted remote insulin pump optimization for people with type 1 diabetes
This study tests an AI-powered tool that suggests insulin pump settings for people with type 1 diabetes, with doctor-approved recommendations delivered to a mobile app.
-
Near-sensor insulin delivery with CGM in people with type 1 diabetes
A small early-feasibility study tests a dual-port insulin patch pump that includes a CGM sensor to see if delivering insulin near the sensor affects glucose readings and whether an automated control algorithm can manage glucose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.